Online inquiry

IVTScrip™ mRNA-Anti-ANGPTL3, REGN 1500(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13752MR)

This product GTTS-WQ13752MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets ANGPTL3 gene. The antibody can be applied in Hypertriglyceridemia&Homozygous familial hypercholesterolemia research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_014495.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 27329
UniProt ID Q9Y5C1
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ANGPTL3, REGN 1500(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ13752MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8596MR IVTScrip™ mRNA-Anti-FOLH1, HuJ591-DOTA(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA HuJ591-DOTA
GTTS-WQ10565MR IVTScrip™ mRNA-Anti-IL23A, LY­3074828(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA LY­3074828
GTTS-WQ5947MR IVTScrip™ mRNA-Anti-IGHE, CL-2C(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CL-2C
GTTS-WQ5767MR IVTScrip™ mRNA-Anti-EGFR, CetuxiMab-GEX(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA CetuxiMab-GEX
GTTS-WQ6171MR IVTScrip™ mRNA-Anti-IGF1R, CP-751871(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA CP-751871
GTTS-WQ2992MR IVTScrip™ mRNA-Anti-KDR, Angiocept(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA Angiocept
GTTS-WQ9520MR IVTScrip™ mRNA-Anti-FOLH1, J-591(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA J-591
GTTS-WQ5174MR IVTScrip™ mRNA-Anti-IL13, CAT-354(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA CAT-354
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW